JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren’s disease murine model
Objectives To examine whether the JAK inhibitor tofacitinib alleviates secretory dysfunction and modulates Th17/Treg balance in a Sjögren’s disease (SjD) murine model.Methods Integrated analysis of SjD transcriptome sequencing (GSE159574, GSE247662) identified key signalling pathways, potential ther...
Gorde:
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2026-12-01
|
| Saila: | Annals of Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.tandfonline.com/doi/10.1080/07853890.2026.2625552 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|